IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Hyperbaric Oxygen Therapy Registry (HBOTR)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the Hyperbaric Oxygen Therapy Registry (HBOTR) is to provide real world patient outcome and side effect information from electronic health records submitted to a specialty specific hyperbaric registry as part of "Stage 2 of Meaningful Use," including data provided to meet PQRS requirements via the registry's QCDR mission.
Goals include understanding the value of HBOT among patients treated for a variety of conditions in relation to the frequency and severity of HBOT side effects. While randomized, controlled trials can establish the efficacy of treatments like HBOT, because they routinely exclude patients with co-morbid conditions common to those patients seen in usual clinical practice, the results of RCTs are usually non-generalizable. Real world data can be used to better understand the effectiveness of HBOT among typical patients, as well as the risks associated with treatment.
| Condition |
|---|
| Air or Gas Embolism Carbon Monoxide Poisoning Clostridial Myositis and Myonecrosis (Gas Gangrene) Crush Injury, Compartment Syndrome & Other Acute Traumatic Ischemias Decompression Sickness Peripheral Arterial Insufficiency and Central Retinal Artery Occlusion Severe Anemia Intracranial Abscess Necrotizing Soft Tissue Infections Osteomyelitis (Refractory) Delayed Radiation Injury (Soft Tissue and Bony Necrosis) Compromised Grafts and Flaps Acute Thermal Burn Injury Idiopathic Sudden Sensorineural Hearing Loss |
| Study Type: | Observational [Patient Registry] |
| Study Design: | Time Perspective: Prospective |
| Target Follow-Up Duration: | 2 Months |
| Official Title: | The Registry of Hyperbaric Oxygen Therapy Treated Patients |
- Outcome of problem treated with HBOT [ Time Frame: 12 Months ]Counts by outcome type
- Major Amputation in Wagner Grade 3, 4, or 5 Diabetic Foot Ulcers Treated with HBOT [ Time Frame: 12 Months ]Scored in % of major amputations
- Preservation of Function with a minor amputation among patients with Wagner Grade 3, 4, or 5 Diabetic Foot Ulcers Treated with HBOT [ Time Frame: 12 Months ]Scored in % of minor amputations
- Complications or Side Effects among patients undergoing Treatment with HBOT [ Time Frame: 12 months ]Scores in % of: otic barotrauma, other barotrauma, central nervous system oxygen toxicity, confinement anxiety, pneumothorax, sudden respiratory distress, visual acuity changes, low blood sugar, and pulmonary oxygen toxicity.
- Appropriate use of HBOT in patients treated for a Diabetic foot ulcer [ Time Frame: 12 Months ]Score in % of cases with appropriate use
| Estimated Enrollment: | 5000 |
| Study Start Date: | January 2005 |
| Estimated Primary Completion Date: | January 2020 (Final data collection date for primary outcome measure) |
The goal of the Hyperbaric Oxygen Therapy Registry (HBOTR) for Wounds is to provide comparative effectiveness data for patients and to understand whether clinical practice guidelines are followed in the use of HBOT.
Hyperbaric Oxygen Therapy (HBOT) is the use of oxygen at greater than one atmosphere (sea level) pressures and is administered by placing the entire patient in a pressurized vessel and having the patient breathe 100% oxygen. The minimum treatment pressure with evidence to support its use among the conditions approved by the Undersea and Hyperbaric Medical society is 2.0 atmospheres absolute (2 ATA) which is an inspired partial pressure of oxygen of approximately 1,520 mmHg. Hyperbaric treatments which provide less than 100% inspired oxygen at the treatment pressure and/or which provide an inspired partial pressure of oxygen less than 760 mmHg are not hyperbaric therapy. Topically applied oxygen is not hyperbaric oxygen therapy. Oxygen is a drug with a well-defined dose response curve as well as acute and chronic drug effects. HBOT also has side effects including oxygen toxicity to many organ systems. The physiological effects of hyperbaric oxygen therapy are well studied. Effectiveness in real world patients is the best current option to understand the role of HBOT in wound healing.
Hospital based outpatient wound centers participating in the US Wound Registry agree to provide data as part of quality initiatives and to meet their Stage 2 Meaningful use criteria. The HBOTR is a subset of the USWR (Chronic Disease Registry) data. All patient data from all participating hyperbaric centers are transmitted to the USWR where data are then used as designated for benchmarking, to satisfy the requirements of PQRS for advanced practitioners, and for data needed by the UHMS to respond to governmental agencies. Data used for effectiveness research are HIPAA de-identified.
Eligibility| Ages Eligible for Study: | Child, Adult, Senior |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patients receiving Hyperbaric Oxygen Therapy for any UHMS Approved indication
Exclusion Criteria:
Contacts and LocationsNo Contacts or Locations Provided
More Information
| Responsible Party: | U.S. Wound Registry |
| ClinicalTrials.gov Identifier: | NCT02483650 History of Changes |
| Other Study ID Numbers: |
CDR004 |
| Study First Received: | May 28, 2015 |
| Last Updated: | May 18, 2016 |
Additional relevant MeSH terms:
|
Wounds and Injuries Ischemia Embolism Necrosis Hearing Loss Poisoning Myositis Soft Tissue Infections Burns Osteomyelitis Compartment Syndromes Hearing Loss, Sensorineural Carbon Monoxide Poisoning Radiation Injuries Gangrene |
Retinal Artery Occlusion Decompression Sickness Gas Gangrene Embolism, Air Pathologic Processes Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Hearing Disorders Ear Diseases Otorhinolaryngologic Diseases Sensation Disorders Neurologic Manifestations Nervous System Diseases Signs and Symptoms |
ClinicalTrials.gov processed this record on July 14, 2017